Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study

Geisler, Jürgen, Haynes, Ben, Anker, Gun, Dowsett, Mitch, Lønning, Per Eystein·2002·Journal of Clinical Oncology
DOI 10.1200/jco.20.3.751

Cited by (606)

Items 401–500 of 606

  1. Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose
    Hidetoshi Yamaya, Kunihiro Yoshida, Jun Kuritani, J. Yonezawa, M. Tsuda, Takashi Shindo, Sekio Nagayama, Aman U. Buzdar · 2005 · Journal of Clinical Pharmacy and Therapeutics
  2. Exemestane for Breast Cancer Prevention: A Feasible Strategy?
    Per Eystein Lønning · 2005 · Clinical Cancer Research
  3. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer.
    Mehmet Alı Nahıt Şendur, Sercan Aksoy, Nurullah Zengin, Kadri Altundağ · 2013 · PubMed
  4. Background and development of aromatase inhibitors
    William R. Miller · 2006 · Birkhäuser Basel eBooks
  5. The Use of Early Adjuvant Aromatase Inhibitor Therapy: Contributions From the BIG 1-98 Letrozole Trial
    John Forbes · 2006 · Seminars in Oncology
  6. Oestrogen suppression—lessons from clinical studies
    Per Eystein Lønning · 2003 · Best Practice & Research Clinical Endocrinology & Metabolism
  7. Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies
    J. Michael Dixon · 2006 · Expert Opinion on Pharmacotherapy
  8. Endocrine symptoms to predict risk of recurrence?
    Kathleen I. Pritchard · 2008 · The Lancet Oncology
  9. Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects
    W. Jonat, Felix Hilpert · 2006 · Journal of Cancer Research and Clinical Oncology
  10. Treatment of established breast cancer in post-menopausal women: Role of aromatase inhibitors
    Srila Samphao, J. Eremin, Mohammed Said ElSheemy, Oleg Eremin · 2009 · The Surgeon
  11. Algorithms for the Treatment of Patients With Metastatic Breast Cancer and Prior Exposure to Taxanes and Anthracyclines
    Elizabeth Anne Comen, Monica Nancy Fornier · 2010 · Clinical Breast Cancer
  12. Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity
    Daniel L. Hertz, Julie A. Douglas, KM Kidwell, Christina L. Gersch, Zeruesenay Desta, AMV Storniolo, Vered Stearns, Todd C. Skaar, Daniel F. Hayes, Norah Lynn Henry et al. · 2021 · Pharmacogenetics and Genomics
  13. Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
    Shanshan Chen, Lan Bo, Dan Lv, Fei Ma · 2022 · Breast Care
  14. Formulation and testing of a non-steroidal aromatase inhibitor intravaginal device for the control of ovarian function in cattle
    Jimena Yapura, Ildikó Badea, Gustavo Zamberlam, Christopher Alan Price, Reuben John Mapletoft, Roger A. Pierson, Jaswant K. Singh, Gregory Paul Adams · 2015 · Animal Reproduction Science
  15. Letrozole: present and future role in the treatment of breast cancer
    Surabhi Amar, Vivek Roy, Edith A. Perez · 2007 · Expert Opinion on Pharmacotherapy
  16. Are all aromatase inhibitors alike?
    Kimberly Blackwell · 2008 · Breast Cancer Research and Treatment
  17. The Evolving Role of Aromatase Inhibitors in Adjuvant Breast Cancer Therapy
    I. Craig Henderson, Martine J Piccart · 2005 · Clinical Breast Cancer
  18. Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
    Tufia C. Haddad, Vera Jean Suman, Karthik V. Giridhar, Kostandinos Sideras, DW Northfelt, Brenda J. Ernst, Ciara Catherine O'Sullivan, Ravinder Jit Singh, Zeruesenay Desta, Prema P. Peethambaram et al. · 2024 · Clinical Cancer Research
  19. CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
    Αngeliki Andrikopoulou, Oraianthi Fiste, Kleoniki Apostolidou, Efthymia Skafida, Christos Markellos, Michalis Liontos, Anastasios I. Kyriazoglou, Meletios Athanasios Dimopoulos, Flora Zagouri · 2021 · Medical Sciences
  20. When to start an aromatase inhibitor: Now or later?
    Julie Doughty · 2011 · Journal of Surgical Oncology
  21. A Comparison of the Efficacy of Two Doses of Letrozole Alone or with Continuous Recombinant Follicle-Stimulating Hormone for Ovulation Induction in Anovulatory Women
    Haiyan Wang, Peng-Sheng Zheng · 2014 · Gynecologic and Obstetric Investigation
  22. Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers
    Marianne Hauglid Flågeng, Alexey A. Larionov, Jürgen Geisler, Stian Knappskog, Wenche S. Prestvik, Geir Bjørkøy, Peer Kåre Lilleng, J. Michael Dixon, William R. Miller, Per Eystein Lønning et al. · 2016 · The Journal of Steroid Biochemistry and Molecular Biology
  23. Synthesis and Biological Evaluation of Some NewN1-[4-(4-Chlorophenylsulfonyl)benzoyl]-N 4-(aryl)-thiosemicarbazides and Products of Their Cyclization
    Ștefania‐Felicia Bărbuceanu, Gabriela Bancescu, Gabriel Șaramet, Florica Bărbuceanu, Constantin C. Draghici, Flavian Ștefan Rădulescu, Aura Elena Ionescu, Simona Negreș · 2013 · Heteroatom Chemistry
  24. In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review
    Yakup Bozkaya, Gökmen Umut Erdem, Nebi Serkan Demirci · 2018 · Journal of Oncology Pharmacy Practice
  25. Click chemistry in silico, docking, quantum chemical calculations, and molecular dynamics simulations to identify novel 1,2,4-triazole-based compounds as potential aromatase inhibitors
    Alexander M. Andrianov, Grigory I. Nikolaev, Yuri V. Kornoushenko, Sergei A. Usanov · 2019 · SN Applied Sciences
  26. [Clinical effect of letrozole in treatment of idiopathic short stature in adolescent boys].
    Yun-Pu Cui, Xinli Wang · 2019 · PubMed Central
  27. Extended adjuvant endocrine therapy of early breast cancer
    Simon Chowdhury, PA Ellis · 2005 · Current Medical Research and Opinion
  28. Safety issues surrounding the use of aromatase inhibitors in breast cancer
    J Jackson, WR Miller, J. Michael Dixon · 2003 · Expert Opinion on Drug Safety
  29. Hydrophilic interaction chromatography–electrospray ionization tandem mass spectrometric analysis of anastrozole in human plasma and its application to a pharmacokinetic study
    Hye Young Ji, Ji‐Hong Sohn, Hye Suk Lee · 2011 · Biomedical Chromatography
  30. The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer
    Christina Isabella Herold, Kimberly Blackwell · 2008 · The Breast
  31. Systemic therapy
    Antonio C. Wolff · 2002 · Current Opinion in Oncology
  32. Aromatase inhibitors and other novel agents in breast cancer treatment
    Shigehira Saji, Masakazu Toi · 2002 · Expert Opinion on Emerging Drugs
  33. A Roundtable Discussion of Aromatase Inhibitors as Therapy for Breast Cancer
    Donald Craig Allred, Michael Baum, Aman U. Buzdar, Robert W. Carlson, Mitch Dowsett, Richard M. Elledge, William John Gradishar, Generosa Grana, Anthony Howell, Eleftherios P. Mamounas · 2003 · The Breast Journal
  34. Role of anastrozole in adjuvant therapy for postmenopausal patients
    Aman U. Buzdar · 2003 · Seminars in Oncology
  35. Aromatase Inhibitors and Their Application to the Treatment of Breast Cancer
    Angela M. H. Brodie · 2002 · CRC Press eBooks
  36. Targeting c-MYC: a potential non-hormonal therapeutic approach for endometriosis treatment
    Warren B. Nothnick, Sachith Polpitiya Arachchige, Paige M. Minchella, Edward B. Stephens, Amanda R. Graham · 2023 · Frontiers in Cell and Developmental Biology
  37. Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors
    Nayoung Kim, Kiven Erique Lukong · 2026 · Cancer Treatment and Research Communications
  38. The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer
    Kamilla Fjermeros, Salim Ghannoum, Stephanie Beate Geisler, Sameer Bhargava, Andliena Tahiri, Jovana Klajic, Torben Lüders, Marie Fongaard, Meh Sameen Nawaz, Tatjana Bosnjak et al. · 2024 · Future Oncology
  39. Endocrine therapy for breast cancer
    Coy Don Heldermon, Matthew J. Ellis · 2006 · Update on Cancer Therapeutics
  40. Understanding the estrogen receptor signaling pathway: focus on current endocrine agents for breast cancer in postmenopausal women
    Adam Brufsky · 2011 · Community Oncology
  41. Effect of Letrozole Administration as a Selective Aromatase Inhibitor on Male Rat's Reproductive Performance.
    A Hmood Jassim, Ahmed S. Abed, Ahmed Kareem Thamer, Hawraa Kareem Judi, Asaed H Enad · 2022 · PubMed Central
  42. Osteoporosis Associated with Cancer Therapy
    Ailleen Heras-Herzig, Wende Kozlow, Sue A. Brown, Theresa A. Guise · 2008 · Elsevier eBooks
  43. Metabolismo de los estrógenos endógenos y cáncer de mama
    Francisco Cóppola, José Nader, Rafael Aguirre · 2005 · DOAJ (DOAJ: Directory of Open Access Journals)
  44. Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference?
    Per Eystein Lønning · 2008 · Anti-Cancer Drugs
  45. Breast Cancer Pharmacogenetics in the Era of Personalized Medicine
    Song Yao, Daria Maghsoudlou, Christine B. Ambrosone · 2012 · Current Breast Cancer Reports
  46. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer
    Henning T. Mouridsen, Per Eystein Lønning, Matthias W. Beckmann, Kimberly Blackwell, Julie Doughty, Joseph Gligorov, Antonio Llombart‐Cussac, André Robidoux, Beat J. K. Thurlimann, Michael Gnant · 2010 · Expert Review of Anticancer Therapy
  47. Comparison of the success rate of letrozole and clomiphene citrate in women undergoing intrauterine insemination
    Robab Davar, M Asgharnia, Mojgan J Tayebi · 2006 · DOAJ (DOAJ: Directory of Open Access Journals)
  48. Optimal Treatment Strategies in Hormone-Responsive Early Breast Cancer: The Role of Aromatase Inhibitors
    Michael Untch, Christian Jackisch · 2007 · Oncology Research and Treatment
  49. Aromatase inhibitors and calcium absorption in early stage breast cancer
    Amye Juliet Tevaarwerk, Mark E. Burkard, Kari Braun Wisinski, Martin Merrill Shafer, Lisa A. Davis, Jyothi Gogineni, Elizabeth M. Crone, Karen E. Hansen · 2012 · Breast Cancer Research and Treatment
  50. Adjuvant Therapy for Patients Who Have Node-Positive Breast Cancer
    Quyen D. Chu, John C. McDonald, Benjamin D.�L. Li · 2006 · Advances in Surgery
  51. Adjuvant Systemic Therapy: Endocrine Therapy
    İbrahim Yıldız, Pınar Mualla Saip · 2016 · Springer eBooks
  52. Comment on “Towards a personalized approach to aromatase inhibitor therapy: a digital microfluidic platform for rapid analysis of estradiol in core-needle-biopsies” by S. Abdulwahab, A. H. C. Ng, M. D. Chamberlain, H. Ahmado, L.-A. Behan, H. Gomaa, R. F. Casper and A. R. Wheeler, Lab Chip, 2017, 17 , 1594
    Per Eystein Lønning · 2017 · Lab on a Chip
  53. Endocrine Therapy for Breast Cancer
    Kari Braun Wisinski, Amye Juliet Tevaarwerk, Ruth M O'Regan · 2017 · Elsevier eBooks
  54. Aromatase inhibitors—Socio-economical issues
    Per Eystein Lønning, Jürgen Geisler · 2005 · The Journal of Steroid Biochemistry and Molecular Biology
  55. Anastrozole: A New Gold Standard of Hormonal Treatment for Breast Cancer?
    Anthony Howell · 2005 · Women s Health
  56. Effects of modified Shu-Gan-Liang-Xue decoction combined with anastrozole on osteoblastic proliferation and differentiation of MC3T3-E1 cells
    Fei Zhou, Shuyan Han, Ning Zhou, Wenxian Zheng, Pingping Li · 2014 · Molecular Medicine Reports
  57. Cancer of the Breast
    Antonio C. Wolff, Susan M. Domchek, Nancy E. Davidson, Virgilio Sacchini, Beryl McCormick · 2014 · Elsevier eBooks
  58. Aromatase inhibitors and inactivators for breast cancer treatment
    Per Eystein Lønning · 2002 · European Journal of Cancer
  59. Progression of endocrine therapies for breast cancer: where are we headed?
    Mónica Arnedos, Ian Smith · 2007 · Expert Review of Anticancer Therapy
  60. Aromatase Inhibitors as First Line Treatment: Treatment Cascade After Failure of Aromatase Inhibitors
    Jacques M Bonneterre · 2003 · Breast Cancer Research and Treatment
  61. Endocrine Effects of Aromatase Inhibitors
    Per Eystein Lønning, Mitch Dowsett · 2010 · Journal of Clinical Oncology
  62. Extended adjuvant therapy with letrozole: reducing the risk of recurrence
    J. Michael Dixon · 2006 · Expert Review of Anticancer Therapy
  63. La Terapia Endocrina Come Terapia Causale: Ruolo Degli Inibitori Dell'aromatasi nel Carcinoma Della Mammella
    Flavia Longo, Giovanni Mansueto · 2003 · Tumori Journal
  64. Effectiveness of Hormonal Therapy for Post-Menopausal Women with Hormone Receptor-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis of Clinical Trials
    Vitalis Chukwuemeka Okwor, Chika Juliet Okwor, Maryjane Ukwuoma, Sara B. Mitha, Martins Nweke · 2025 · Medical Principles and Practice
  65. Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane
    Bjørn-Erik Bertelsen, Bjørg Almås, Kamilla Fjermeros, Kristin Viste, Stephanie Beate Geisler, Torill Sauer, Knut Selsås, Jürgen Geisler · 2024 · Breast Cancer Research and Treatment
  66. Endocrine Therapy and Its Effect on Sexual Function
    Shari Beth Goldfarb · 2015 · American Society of Clinical Oncology Educational Book
  67. Hormonal Therapy: Current and New Directions
    James N. Ingle · 2003 · The Breast Journal
  68. Polymorphic genetic variations of Cytochrome P450 19A1 and T-cell leukemia 1A genes in the Tamil population
    Gurusamy Umamaheswaran, Kadambari Dharanipragada, Annan Sudarsan Arun Kumar, Mohan Revathy, Raj Anjana, Chandrasekaran Adithan, Steven Aibor Dkhar · 2014 · Environmental Toxicology and Pharmacology
  69. Letrozole: A Well-Tolerated and Effective Treatment for Breast Cancer
    Nigel James Bundred · 2006 · Women s Health
  70. A review of exemestane in the management of breast cancer
    Nan Soon Wong, Kathleen I. Pritchard · 2005 · Expert Opinion on Pharmacotherapy
  71. Treatment of Metastatic Breast Cancer: Endocrine Therapy
    Fatma Şen, Adnan Aydıner · 2016 · Springer eBooks
  72. Growth of human breast cancers in Peromyscus
    Vimala Kaza, Elena Farmaki, Amanda Havighorst, Janet P. Crossland, Ioulia Chatzistamou, Hippokratis Kiaris · 2018 · Disease Models & Mechanisms
  73. Preoperative Endocrine Therapy: Preferred Therapy for Whom?
    E. Jane Macaskill, J. Michael Dixon · 2011 · Current Breast Cancer Reports
  74. Management of male breast cancer
    Nikolay V. Dimitrov, Sunil Nagpal, Shalini Chitneni · 2008 · Oncology Reviews
  75. Effect of Aromatase Inhibitors on Bone Mineral Density in a Japanese Breast Cancer Population
    Takeshi Akiyoshi, Yuka Shimomura, Shinichi Masuda, Yasushi Okamoto, Sumiko Hiura, Hiroyoshi Kato, Toru Asayama, Hisakazu Ohtani · 2013 · Drug Metabolism and Pharmacokinetics
  76. Targeting Breast Cancer
    Terrie E. Mellington, Margaret M. Fields · 2008 · The Nurse Practitioner
  77. Assessment of Quality of Life and Safety in Postmenopausal Breast Cancer Patients Receiving Letrozole as an Early Adjuvant Treatment
    Yong Sik Jung, Soo Jung Lee, Juneyoung Lee, Woo Chul Noh, Seok Jin Nam, Byeong‐Woo Park, Youngtae Bae, Sung-Soo Kang, Heung Kyu Park, Jung-Han Yoon et al. · 2018 · Journal of Breast Cancer
  78. Hormone Responsive Cancers
    Richard J. Santen, Linda Duska, Stephen H. Culp · 2013 · Elsevier eBooks
  79. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors
    Ian S. Fentiman · 2006 · International Journal of Clinical Practice
  80. Managing Aromatase Inhibitor-Associated Bone Loss in Breast Cancer
    Allan Lipton, Michael Gnant, Matti Aapro · 2007 · Women s Health
  81. Role of endocrine therapy in breast cancer—where are we going?
    Per Eystein Lønning · 2003 · Best Practice & Research Clinical Endocrinology & Metabolism
  82. Do all aromatase inhibitors have similar efficacy and safety?
    Mehmet Alı Nahıt Şendur, Burak Bi̇lgi̇n, Mutlu Hızal, Nuriye Özdemir, Muhammed Bülent Akıncı, Didem Şener Dede, Bülent Yalçın · 2017 · Future Oncology
  83. Randomized empirical likelihood test for ultra-high dimensional means under general covariances
    Yuexin Chen, Lixing Zhu, Wangli Xu · 2025 · Journal of the Royal Statistical Society Series B (Statistical Methodology)
  84. Near Final Height in Males treated with Aromatase Inhibitors
    Athanasia Bouliari, Anjile An, Oksana Lekarev, Karen Lin‐Su · 2026 · Journal of Clinical Research in Pediatric Endocrinology
  85. Synthesis, ADMET, DFT analysis, molecular docking, and multitarget bioactivity of a 2,5-dihydroxybenzaldehyde Schiff base: Insights into antioxidant, anti-inflammatory, and selective anticancer activity
    Amina Alouache, Abdellatif Ben kaida, Nadjib Benosmane, Taklit Maddi, Marı́a C. Gutiérrez, M. Luisa Ferrer, Francisco del Monte · 2026 · Journal of Molecular Structure
  86. Endokrine Therapie des metastasierten Mammakarzinoms
    Sibylle Loibl, Gϋnter von Minckwitz, M. Kaufmann · 2003 · Der Gynäkologe
  87. Cancer of the Breast
    Robert G. Parker, Nora Anita Janjan, Michael T. Selch · 2003 · Medical radiology
  88. The third-generation aromatase inhibitors: a clinical overview
    Aman U. Buzdar · 2008 · Birkhäuser Basel eBooks
  89. Aromatase Inhibitors and Osteoporosis - Risk, Prevention and Treatment Review
    Wajeeha Razaq Takemi Tanaka, Mohammad Razaq · 2015 · Journal of Osteoporosis and Physical Activity
  90. Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane
    Peter A. Canney · 2010 · Breast Cancer Targets and Therapy
  91. Examination of the use of Exemestane in patients with metastatic breast cancer
    Seiki Takashima, Sachiko Kiyoto, Mina Takahashi, Fumikata Hara, Daisuke Takabatake, Kenjiro Aogi, Shozo Ohsumi · 2011 · Breast Cancer
  92. Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer
    Mehmet Alı Nahıt Şendur, Sercan Aksoy, Muhammed Bülent Akıncı, Nuriye Özdemir, Didem Şener Dede, Kadri Altundağ, Nurullah Zengin, Bülent Yalçın · 2015 · Future Oncology
  93. InforMatrix Aromatase Inhibitors in Breastcancer
    R. Janknegt · 2016 · Journal of Pharmaceutical Care & Health Systems
  94. The Role of Rehabilitation in Optimizing Bone Health in Cancer Survivors
    Noble G. Jones, Diana H. Presno Rubin · 2024 · Current Physical Medicine and Rehabilitation Reports
  95. Prediction of Response to Aromatase Inhibitors in Breast Cancer
    Alexey A. Larionov, William R. Miller · 2015 · Resistance to targeted anti-cancer therapeutics
  96. The Modulating Influence of Tea Polyphenols on Estrogen Metabolism in Asian and Caucasian Populations
    Maria Kapiszewska, Anna Merklinger-Gruchała, Grażyna Jasieńska · 2012 · Elsevier eBooks
  97. Assay of serum E2 concentration in postmenopausal breast cancer patients using a high-sensitivity RIA method is generally useful
    Masami Morimoto, Masako Takahashi, Junko Honda, Takahiro Yoshida, Mitsuteru Yoshida, Hiroaki Toba, Issei Imoto, Akira Tangoku, Mitsunori Sasa · 2016 · The Journal of Medical Investigation
  98. Click Chemistry in Medicinal Chemistry for Comprehensive Medicinal Chemistry III
    P. Thirumurugan, Krzysztof Jóźwiak · 2016 · Elsevier eBooks
  99. Study the Effect of Anastrozole on Estradiol and Cytochrome P450 (Aromatase Enzyme) in Postmenopausal Breast Cancer Patients
    Mays Abd-Allateef, Firas Hassan, Wieeam Abdulfattah Saleh‎ · 2016 · Journal of Al-Nahrain University-Science
  100. Adjuvant aromatase inhibition: more options for patients
    Luc Yves Dirix · 2018 · The Lancet Oncology